Sanofi (SNY) Q2 2026 earnings review
Blockbuster Quarter Masked by Massive R&D Failure
Sanofi reported a spectacular top-line quarter, with sales up 17.8% (CER) and Dupixent crossing the €5 billion mark for the first time. The strong operational performance allowed management to upgrade FY26 sales guidance to ~10%. However, beneath the booming revenue lies a devastating failure in the R&D pipeline. Amlitelimab, a candidate management previously touted with 'extremely high confidence,' was abruptly discontinued for atopic dermatitis, triggering a €1.03 billion intangible impairment. While Business EPS surged 33.3%, unadjusted IFRS net income crashed 91% to just €343M. Investors must weigh an unstoppable commercial engine against shattered credibility in late-stage pipeline execution.
🐂 Bull Case
Dupixent sales surged 37.6% to €5.2 billion, accelerating from recent quarters. Strong demand across all geographies proves that competitor launches have done nothing to dent its trajectory.
The recent Pharma launches segment rocketed 48.3% to €1.3 billion. Ayvakit and ALTUVIIIO are successfully diversifying the top line and reducing single-product dependency.
🐻 Bear Case
The discontinuation of amlitelimab for AD, alongside itepekimab and balinatunfib, is a catastrophic failure. Management had heavily hyped these assets in 2025, and their failure raises serious questions about Sanofi's internal innovation capabilities.
Vaccines declined 4.7%, dragged down by a 62% collapse in influenza vaccines and macro-driven structural headwinds in China due to declining birth rates.
⚖️ Verdict: ⚪
Neutral. The commercial execution is flawless and the guidance upgrade is impressive, but a €1 billion writedown on your flagship pipeline asset is a massive red flag. The lack of a credible post-Dupixent pipeline caps the upside.
Key Themes
The Amlitelimab Debacle and Pipeline Collapse
In a shocking reversal, Sanofi discontinued amlitelimab for atopic dermatitis—an asset that leadership claimed had 'progressively increasing efficacy' and 'extremely high confidence' just two quarters ago. Management admitted it 'would not represent a meaningful improvement to the standard of care.' This forced a €952M impairment loss. Compounding the damage, itepekimab (COPD) and balinatunfib (Crohn's) were also discontinued. This specific data point severely contradicts management's ongoing narrative of a successful 'R&D transformation'.
Dupixent Crosses the €5 Billion Threshold
Dupixent sales accelerated to 37.6% YoY growth, hitting €5.15 billion for the quarter. US sales were particularly dominant, up 42.8%. The drug continues to benefit from strong volume growth and favorable gross-to-net adjustments, proving that Sanofi can effectively commercialize its anchor asset regardless of emerging competition.
Pharma Launches Provide Critical Diversification
Recent launches grew 48.3% to €1.3 billion, highlighting successful execution on recent acquisitions. ALTUVIIIO reached €349M (+23.7%), continuing to steal market share in hemophilia A. Ayvakit contributed €190M, though US sales face margin pressure from higher government rebates due to Blueprint becoming part of Sanofi.
Macro Headwinds Stalling the Vaccine Engine
Vaccines sales fell 4.7% to €1.15 billion. While partially driven by a tough YoY comparison for influenza (-61.7%), macro headwinds are inflicting permanent damage: Polio/pertussis/hib (PPH) vaccines dropped 21.2% in the Rest of World segment, explicitly driven by a decline in childbirths in China.
Favorable Product Mix Drives Gross Margin Expansion
Business gross margin expanded by a remarkable 3.8 percentage points to 81.2%. This was driven by a mix shift toward high-margin specialty care (Dupixent, Rare Diseases) and a one-time reversal of over €200M in manufacturing provisions following the regulatory approval of Sarclisa SC.
R&D Expense Surges Due to Pipeline Failures
R&D expenses spiked 17.9% to €2.23 billion. Paradoxically, this was not driven by accelerating innovation, but by over €200 million in wind-down costs associated with the discontinuation of amlitelimab, itepekimab, and balinatunfib.
Regeneron Profit Sharing Taking a Heavy Toll
As Dupixent scales, the cost of the Regeneron alliance is eating heavily into operating income. Profit sharing expense surged to €1.97 billion for Q2 alone, up from €1.36 billion a year ago. While Sanofi is growing the top line aggressively, a significant chunk of that value is being transferred straight to its partner.
Other KPIs
Accelerating. BOI increased 35.8% at constant exchange rates. Operating leverage was strong, as the 3.8pp gross margin expansion outpaced the 9.0% increase in SG&A expenses, yielding a BOI margin of 28.4%.
Stable. Up 51.5% compared to H1 2025 (€2.46 billion). The strong top-line cash generation was partially offset by a negative change in working capital (€412 million) and €967 million in capital expenditures.
Guidance
Accelerating. Upgraded from the previous 'high single-digit' (~8.5%) expectation, signaling high confidence in Dupixent's H2 trajectory and the continued ramp of the new pharma launches.
Stable. Maintained from prior quarters. Implies low double-digit growth (~10-12%), supported by the completion of the €1 billion share buyback program and expanding gross margins.
Decelerating. Revised upward from the previously guided 'c.20%'. Management explicitly tied this increase to the financial fallout from decisions made on the clinical pipeline.
Key Questions
Accountability for R&D Failures
Just months ago, leadership expressed 'extremely high confidence' in amlitelimab, yet it has now been completely discontinued for AD. What specific failures in early clinical readouts or diligence led to this massive miscalculation, and how is capital allocation being adjusted?
The Post-Dupixent Vacuum
With amlitelimab, itepekimab, and balinatunfib all scrapped, the late-stage immunology pipeline looks suddenly barren. What is the explicit strategy to replace the revenue vacuum when Dupixent inevitably faces LOE pressures next decade?
Vaccine Segment Turnaround
With the structural decline in Chinese childbirths severely impacting PPH vaccines and influenza facing tough pricing/volume comps, is the vaccine segment expected to remain a drag on total company growth into 2027?